Literature DB >> 26118618

Long-term survival after curative resection for pancreatic ductal adenocarcinoma--Surgical treatment.

G Benassai1, G Quarto2, S Perrotta2, E Furino2, G L Benassai2, B Amato2, T Bianco2, G De Palma2, P Forestieri2.   

Abstract

INTRODUCTION: Recent reports have demonstrated improvement in the 5-years serviva with resecate ductal adenocarcinoma. The aim of study is to determinate the factor influencing long-term survival after DCP.
MATERIALS AND METHODS: We have critically reviewed a group of 85 patients how were admitted to our department with diagnosis of ductal adenocarcinoma of the head of pancreas between January 1974 and January 1998.
RESULTS: Patients were stratified according to stage using TNM classification; in stage I 31 patients with 5 T1aN0M0 disease, 11 patients with T1bN0M0 and 15 patients T2N0M0 disease. By contrast, in stage III 54 patients with 48 patients T2N1M0 and 6 patients with T3N1M0. Tumour size was recorded for 72 patients with a median of 3.8 cm. The R1 dissection was performed in 67 patients. The R2 resection was performed in 18 patients. In our series we verified and analysed the histopathologic features of 5 patients with 15-years survival (5.8%). The features regard age, male or female, tumours size, stage and positive lymph node resection. DISCUSSION: We found a specifically subset of patients where the combination of prognostic factors, in particular, negative surgical margins R0, tumour size ≤ 30 mm and the absence of lymph node metastasis independently reduced the mortality indicating that earlier tumour detection and histologically curative resection are important factors contributing to long term survival and healing of ductal adenocarcinoma of the head of the pancreas.
Copyright © 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Long term survival; Pancreatic cancer; Prognostic factors

Mesh:

Year:  2015        PMID: 26118618     DOI: 10.1016/j.ijsu.2015.06.050

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  12 in total

1.  Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma.

Authors:  Rong Lin; Chao-Qun Han; Wei-Jun Wang; Jun Liu; Wei Qian; Zhen Ding; Xiao-Hua Hou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

2.  Surgical Margin Status of Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Radical Intent: Risk Factors for the Survival Impact of Positive Margins.

Authors:  Chun-Chi Lai; Shang-Yu Wang; Chien-Hung Liao; Jun-Te Hsu; Kun-Chun Chiang; Ta-Sen Yeh; Tsann-Long Hwang; Chun-Nan Yeh
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

3.  Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Aino Salmiheimo; Harri Mustonen; Ulf-Håkan Stenman; Pauli Puolakkainen; Esko Kemppainen; Hanna Seppänen; Caj Haglund
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

4.  Challenging the limits in pancreatic surgery: A case report.

Authors:  Johannes Lemke; Stefan A Schmidt; Marko Kornmann; Karl-Heinz Orend; Doris Henne-Bruns
Journal:  Int J Surg Case Rep       Date:  2016-11-15

5.  Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.

Authors:  Lei Huang; Yesilda Balavarca; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Vesna Zadnik; Maja Primic-Žakelj; Margit Mägi; Robert Grützmann; Marc G Besselink; Petra Schrotz-King; Hermann Brenner; Lina Jansen
Journal:  BMC Med       Date:  2019-03-25       Impact factor: 8.775

6.  Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection.

Authors:  Junming Xu; Shaocheng Lyu; Yang Zhao; Xinxue Zhang; Zhe Liu; Xin Zhao; Qiang He
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

7.  Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center.

Authors:  Jiangning Gu; Zhiwei Xu; Yang Ma; Hao Chen; Di Wang; Xiaxing Deng; Dongfeng Cheng; Junjie Xie; Jiabin Jin; Xi Zhan; Yuan Shi; Yusheng Shi; Youwei Zhu; Baiyong Shen; Chenghong Peng
Journal:  J Gastrointest Oncol       Date:  2020-04

8.  Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection.

Authors:  Ning Pu; Shanshan Gao; Yadong Xu; Guochao Zhao; Yang Lv; Abulimiti Nuerxiati; Jian-Ang Li; Dansong Wang; Xuefeng Xu; Tiantao Kuang; Xiaolin Wang; Wenhui Lou; Lingxiao Liu; Wenchuan Wu
Journal:  J Cancer       Date:  2017-09-20       Impact factor: 4.207

9.  Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.

Authors:  Ge Li; Jiang-Zhi Chen; Shi Chen; Sheng-Zhe Lin; Wei Pan; Ze-Wu Meng; Xin-Ran Cai; Yan-Ling Chen
Journal:  Cancer Med       Date:  2020-03-17       Impact factor: 4.452

Review 10.  Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions.

Authors:  Maximilian Brunner; Zhiyuan Wu; Christian Krautz; Christian Pilarsky; Robert Grützmann; Georg F Weber
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.